Abstract
Viruses manipulate cellular metabolism and macromolecule recycling processes like autophagy. Dysregulated metabolism might lead to excessive inflammatory and autoimmune responses as observed in severe and long COVID-19 patients. Here we show that SARS-CoV-2 modulates cellular metabolism and reduces autophagy. Accordingly, compound-driven induction of autophagy limits SARS-CoV-2 propagation. In detail, SARS-CoV-2-infected cells show accumulation of key metabolites, activation of autophagy inhibitors (AKT1, SKP2) and reduction of proteins responsible for autophagy initiation (AMPK, TSC2, ULK1), membrane nucleation, and phagophore formation (BECN1, VPS34, ATG14), as well as autophagosome-lysosome fusion (BECN1, ATG14 oligomers). Consequently, phagophore-incorporated autophagy markers LC3B-II and P62 accumulate, which we confirm in a hamster model and lung samples of COVID-19 patients. Single-nucleus and single-cell sequencing of patient-derived lung and mucosal samples show differential transcriptional regulation of autophagy and immune genes depending on cell type, disease duration, and SARS-CoV-2 replication levels. Targeting of autophagic pathways by exogenous administration of the polyamines spermidine and spermine, the selective AKT1 inhibitor MK-2206, and the BECN1-stabilizing anthelmintic drug niclosamide inhibit SARS-CoV-2 propagation in vitro with IC<sub>50</sub> values of 136.7, 7.67, 0.11, and 0.13 μM, respectively. Autophagy-inducing compounds reduce SARS-CoV-2 propagation in primary human lung cells and intestinal organoids emphasizing their potential as treatment options against COVID-19.
Introduction
Viruses are the ultimate metabolic hijackers. To replicate, they must reprogram the host cell to provide a steady stream of energy and molecular building blocks, such as amino acids, lipids, and nucleotides. A critical part of cellular maintenance is autophagy, a process where cells capture damaged components or invading pathogens in vesicles called autophagosomes and fuse them with lysosomes for degradation. While some viruses utilize autophagy components to build replication factories, others actively suppress it to avoid degradation. This study investigates how SARS-CoV-2 manipulates these pathways and whether restoring cellular recycling can serve as a host-targeting antiviral strategy.
Methods
The researchers employed a multi-omic, cross-species approach to map the effects of SARS-CoV-2 infection:
- Metabolomics: Targeted metabolic profiling on VeroFM (monkey kidney) and Calu-3 (human lung) cells to identify shifts in central carbon metabolism.
- Functional Autophagy Assays: Tracking autophagosome formation and fusion using Western blotting and fluorescence microscopy (mRFP-EGFP-LC3B reporter).
- Transcriptomics: Analysis of single-cell and single-nucleus RNA sequencing data from COVID-19 patient mucosal brushes and post-mortem lung samples.
- Validation Models: Findings were confirmed in Syrian hamsters, primary human airway epithelial cells (AEC), and human intestinal organoids.
- Drug Screening: Testing of autophagy-inducing compounds, including polyamines (spermidine/spermine), the AKT1 inhibitor MK-2206, and niclosamide.
Results
Metabolic Reprogramming and the "Metabolic Glut"
Infected cells exhibit a massive accumulation of amino acids and nucleotides. This is not merely a byproduct; the virus triggers a translational shutoff of host proteins while accelerating the ubiquitin-proteasome system to create a resource pool for viral assembly. Metabolomic analysis across different cell lines confirmed significant enrichment in pathways related to amino acid metabolism and nucleotide synthesis.
The Autophagy Fusion Blockade
SARS-CoV-2 does not prevent autophagosomes from forming; instead, it prevents them from fusing with lysosomes. This results in an accumulation of "clogged" autophagosomes, marked by high levels of LC3B-II and P62 proteins. This blockade was confirmed in lab models, infected hamsters, and lung samples from human COVID-19 victims.
Molecular Sabotage of Autophagy
The virus actively suppresses autophagy through the AKT1/SKP2 pathway. Activation of AKT1 leads to the activation of SKP2, which then targets Beclin-1 (BECN1)—a master regulator of autophagy—for degradation. Simultaneously, the virus reduces the activity of AMPK and ULK1, the primary "on-switches" for autophagy initiation.
Potent Inhibition via Autophagy Induction
Because the virus relies on suppressing this host pathway, drugs that stabilize BECN1 or inhibit the AKT1/SKP2 axis can "unlock" the autophagy process. Several compounds showed strong antiviral activity in vitro:
- MK-2206 (AKT1 inhibitor): IC<sub>50</sub> of 0.11 μM.
- Niclosamide (BECN1 stabilizer): IC<sub>50</sub> of 0.13 μM.
- Spermine/Spermidine: IC<sub>50</sub> of 7.67 μM and 136.7 μM, respectively.
These compounds significantly reduced viral propagation in complex human intestinal organoids and primary human lung cells, demonstrating high translational potential.
Discussion
While these findings highlight promising therapeutic targets, several challenges remain. Niclosamide is highly potent but has poor systemic absorption, suggesting that inhalable formulations might be necessary for lung delivery. Furthermore, while spermidine concentrations required for inhibition are high, intracellular levels can be boosted by supplementation. Future work is needed to identify the specific viral proteins interacting with the AKT1/SKP2 pathway and to conduct clinical trials to determine the optimal timing for autophagy induction in COVID-19 patients.
Summary updated